Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PAN Gene Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 0 results

Early research (Phase 1)Looking for participantsNCT07252479
What this trial is testing

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Who this might be right for
Solid Tumors (Phase 1)RAS Mutation
Adlai Nortye Biopharma Co., Ltd. 118
Early research (Phase 1)Active Not RecruitingNCT06607185
What this trial is testing

The Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer+2 more
Eli Lilly and Company 750
Early research (Phase 1)Study completedNCT01473095
What this trial is testing

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Who this might be right for
Solid TumorMalignant LymphomaTumor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 120